Miguel Forte

President International Society for Cell & Gene Therapy; Board Member ARM; Biotech CEO

[Miguel Forte @7MiguelForte]

RT @BLLPHD: Is Germline Editing Feasible and Should it be Permissible? I joined @UrnovFyodor @kiranmusunuru @ISCTglobal President @7Miguel…

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Many questions unanswered from the FDA report: https://t.co/TxSER3Go0n
Colleagues I've consulted with are very surprised by this as we haven't seen. Questions:
-what was the clinical status of the patients in terms of immunosuppression, prior therapy, conditioning chemotherapy, evidence of prior clonal hematopoiesis?
-some unknown number of patients may not be in follow up as recommended, were there undetected/unknown early warning signs?
-related to the product, what was the vector copy number? Was integration site analysis performed?
*It’s important to put into context the remote though real risk when compared to conventional chemotherapy that has significant long and short term side effects, including genotoxicity and predisposition to secondary cancers.

[Patrick J. Hanley 🧬 @DrPHanley]

Live from Paris 🇫🇷 it’s @isct TV! #ISCT2023

[ISCT @ISCTglobal]

Another full room for the Translation to Clinic Plenary, providing insights into the road to the clinic!

#ISCT2023

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

#ISCT2023 @ISCTglobal #Paris🇫🇷

[ISCT @ISCTglobal]

We are officially in Paris!

We are excited to kick off our pre-meeting day with the ISCT Global Regulators Summit on the Use of Unproven Cell and Gene Products, bringing together experts from 15 regulatory agencies and government agencies from across the globe.

#ISCT2023

[Miguel Forte @7MiguelForte]

@BLLPHD 😱

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

With @ISCTglobal President-Elect @7MiguelForte surveying the #celltherapy & #genetherapy innovation landscape in #Philly

[Miguel Forte @7MiguelForte]

@BLLPHD @ISCTglobal Great tour. Great friendship. Fantastic set up! Thank you Bruce!

[AdBio Partners @AdBiopartners]

[Event] Join @7MiguelForte #entrepreneur in Residence at Adbio at the @AdTherapiesConf in #London on 14-15 March.
Experts will break down #clinicaltrials for the #cellandgenetherapy space, providing tips for improving #clinical outcomes and clinical data generation. More below

[AdTherapiesCongress @AdTherapiesConf]

Panel: Revision of ATMP legislation

✴️ Peter Marks - @FDA
✴️ @7MiguelForte - @AdBiopartners
✴️ Shinichi Okudaira - Pharmaceuticals and Medical Devices Agency @EURegulatory
✴️ Klaus Cichutek - @PEI_Germany
✴️ Paolo Morgese - @alliancerm

Book now: //buff.ly/3wobiDU

[Alliance for Regenerative Medicine (ARM) @alliancerm]

Miguel Forte, President-Elect of @ISCTglobal and ARM Board Member, delivered powerful closing remarks today at #ATMPEurope.

1/3 "As a European, as a drug developer, as an assessor, I'm stressed to see state of Europe. We have a duty for our patients, our science to do better."

[Miguel Forte @7MiguelForte]

@BLLPHD @ADaviesDHCG @OrentasR @cells_nnm @pknoepfler Indeed…

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

🚨 @Tribeca Film Festival to Debut Documentary Tracing the Path to @PennMedicine & @ChildrensPhila Transformative, Personalized #Cancer Therapy
#celltherapy #genetherapy #CARTCell #immunotherapy
https://t.co/fl8ZLoQ18s

[Miguel Forte @7MiguelForte]

@medicine_maker @BLLPHD @ISCTglobal @massdomi @JacquesGalipeau It is an honour to be part of the 2022 Medicine Maker power list in such a prestigious company.

[BioSenic SA @BioSenicSA]

Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - https://t.co/2WJfvoGD7k

[BioSenic SA @BioSenicSA]

Bone Therapeutics appoints industry cell therapy expert, Anthony Ting, PhD as Chief Scientific Officer - https://t.co/oYCf5Iph2E

[BioSenic SA @BioSenicSA]

Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region | Bone Therapeutics agrandit son portefeuille de produits avec le soutien de la Région Wallonne
- https://t.co/CUpHkHT6k9

[BioSenic SA @BioSenicSA]

Dr. Fortems presents results of our Phase II/III clinical trial with our product JTA-004 at the European E-Congress of Rheumatology 2020.
@eular_org #EULAR2020 #EULAR2020goesvirtual

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

Business RE-IMAGINED: Your invitation to ISCT 2020 Paris Virtual #celltherapy #genetherapy #regenerativemedicine #immunotherapy #commercialization #biotech #bioengineering @ISCTGlobal https://t.co/O5xnXIibNE